Shih-Hao Huang
Overview
Explore the profile of Shih-Hao Huang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
484
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chan L, Huang S, Chen J, Hsu C
J Eur Acad Dermatol Venereol
. 2025 Feb;
PMID: 39912336
No abstract available.
2.
Kan S, Zhang L, Wang Y, Chiang C, Chen M, Huang S, et al.
Nanomaterials (Basel)
. 2024 Dec;
14(24).
PMID: 39728581
Oral squamous-cell carcinoma (OSCC) poses significant treatment challenges due to its high recurrence rates and the limitations of current therapies. Titanium dioxide (TiO) nanoparticles are promising radiosensitizers, while bacterial outer...
3.
Huang S, Wang C, Shen P, Liu Z, Chen S, Tien Y, et al.
J Orthop Res
. 2024 Oct;
43(2):252-263.
PMID: 39358851
Rotator cuff tendinopathy is a common musculoskeletal disorder with limited pharmacological treatment strategies. This study aimed to investigate tenocytes' functional in vitro response from a ruptured supraspinatus tendon to suramin...
4.
Chang C, Chang C, Huang S, Lee C, Ko P, Lin C, et al.
Ann Clin Microbiol Antimicrob
. 2024 Feb;
23(1):15.
PMID: 38350983
Purpose: Multidrug-resistant (MDR) bacteria impose a considerable health-care burden and are associated with bronchiectasis exacerbation. This study investigated the clinical outcomes of adult patients with bronchiectasis following MDR bacterial infection....
5.
Chang C, Huang S, Huang H, Lin M, Lee C, Lee H, et al.
Ther Adv Med Oncol
. 2024 Jan;
16:17588359231221907.
PMID: 38249337
Background: Lung cancers are common worldwide. First-line targeted therapy and chemotherapy are both standard treatments in the current guidelines. With the development of new anticancer therapy, the lifespan of patients...
6.
Huang C, Lee K, Chang J, Tzeng H, Huang S, Yu L, et al.
Oncologist
. 2023 Aug;
29(1):e81-e89.
PMID: 37561957
Background: Tyrosine kinase inhibitor (TKI) treatment has been identified to be a risk factor for metabolic syndrome and cardiovascular diseases (CVDs) in patients diagnosed with chronic myeloid leukemia (CML). However,...
7.
Tsai T, Yu L, Yu M, Huang S, Lin A, Lee K, et al.
Ther Adv Hematol
. 2023 Jun;
14:20406207231179331.
PMID: 37359893
Background: Polycythemia vera (PV) patients often experience constitutional symptoms and are at risk of thromboembolism as well as disease progression to myelofibrosis or acute myeloid leukemia. Not only is PV...
8.
Shen P, Huang S, Liu Z, Lu C, Chou S, Tien Y
Int Immunopharmacol
. 2023 May;
120:110295.
PMID: 37182454
Osteoarthritis (OA)-the most prevalent of arthritis diseases-is a complicated pathogenesis caused by cartilage degeneration and synovial inflammation. Suramin has been reported to enhance chondrogenic differentiation. However, the therapeutic effect of...
9.
Tse M, Huang S, Tsai Y, Li C
Br J Neurosurg
. 2022 Dec;
:1-4.
PMID: 36583395
Purpose: Penetrating brain injury (PBI), a relatively uncommon injury, is associated with remarkable secondary complications such as vascular injury, intracranial haemorrhage, infection, and mortality. Non-missile PBI (NMPBI) due to sharp...
10.
Huang S, Shedden K, Chang H
Biometrics
. 2022 Dec;
79(3):2394-2403.
PMID: 36511353
In data analysis using dimension reduction methods, the main goal is to summarize how the response is related to the covariates through a few linear combinations. One key issue is...